MOA
MCID: OLG006
MIFTS: 35

Oligoastrocytoma (MOA)

Categories: Neuronal diseases, Rare diseases

Aliases & Classifications for Oligoastrocytoma

MalaCards integrated aliases for Oligoastrocytoma:

Name: Oligoastrocytoma 52 58 29 17
Mixed Oligoastrocytoma 58 71
Mixed Oligodendroglioma-Astrocytoma 71
Oligoastrocytoma Mixed 54
Moa 58

Classifications:

Orphanet: 58  
Rare neurological diseases


External Ids:

ICD10 via Orphanet 33 C71.9
UMLS via Orphanet 72 C0280793
Orphanet 58 ORPHA251656
UMLS 71 C0280793 C0547065

Summaries for Oligoastrocytoma

NIH Rare Diseases : 52 Oligoastrocytoma is a brain tumor that forms when two types of cells in the brain, called oligodendrocytes and astrocytes , rapidly increase in number to form a mass. These brain cells are known as glial cells, which normally protect and support nerve cells in the brain. Because an oligoastrocytoma is made up of a combination of two cell types, it is known as a mixed glioma . Oligoastrocytomas usually occur in a part of the brain called the cerebrum and are diagnosed in adults between the ages of 30 and 50. The exact cause of this condition is unknown.

MalaCards based summary : Oligoastrocytoma, also known as mixed oligoastrocytoma, is related to anaplastic oligodendroglioma and mixed glioma, and has symptoms including seizures and headache. An important gene associated with Oligoastrocytoma is IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2). The drugs Carmustine and Lomustine have been mentioned in the context of this disorder. Affiliated tissues include brain, testes and spinal cord.

Wikipedia : 74 Oligoastrocytomas are a subset of brain tumors that present with an appearance of mixed glial cell... more...

Related Diseases for Oligoastrocytoma

Diseases related to Oligoastrocytoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 90)
# Related Disease Score Top Affiliating Genes
1 anaplastic oligodendroglioma 30.5 MGMT IDH2
2 mixed glioma 29.7 MGMT IDH2 GFAP
3 oligodendroglioma 29.5 MGMT IDH2 HSPG2 GFAP
4 grade iii astrocytoma 29.5 MGMT IDH2 GFAP
5 malignant glioma 29.5 MGMT GFAP
6 glioblastoma multiforme 29.3 MGMT IDH2 GFAP
7 meningioma, familial 29.1 MGMT GFAP
8 fibrillary astrocytoma 29.0 MGMT IDH2 GFAP
9 brain cancer 28.7 MGMT IDH2 GFAP
10 anaplastic oligoastrocytoma 12.8
11 glioma 11.6
12 astrocytoma 10.7
13 glial tumor 10.5
14 intracranial hypertension 10.1
15 multiple sclerosis 10.0
16 medulloblastoma 10.0
17 syringomyelia, noncommunicating isolated 10.0
18 mismatch repair cancer syndrome 10.0
19 autism x-linked 2 10.0
20 ataxia and polyneuropathy, adult-onset 10.0
21 leukemia, acute myeloid 10.0
22 meningioma, radiation-induced 10.0
23 alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity 10.0
24 leukemia, acute lymphoblastic 10.0
25 hypophosphatemia 10.0
26 focal dystonia 10.0
27 cerebellar medulloblastoma 10.0
28 scoliosis 10.0
29 myelomeningocele 10.0
30 childhood acute myeloid leukemia 10.0
31 cysticercosis 10.0
32 dermatomyositis 10.0
33 spinal meningioma 10.0
34 visual epilepsy 10.0
35 neutropenia 10.0
36 thrombocytopenia 10.0
37 status epilepticus 10.0
38 epilepsy 10.0
39 dysembryoplastic neuroepithelial tumor 10.0
40 adult oligodendroglioma 10.0
41 demyelinating disease 10.0
42 myelitis 10.0
43 syringomyelia 10.0
44 mutism 10.0
45 secretory meningioma 10.0
46 lymphoplasmacyte-rich meningioma 10.0
47 dystonia 10.0
48 paraplegia 10.0
49 gliomatosis cerebri 10.0
50 lymphopenia 10.0

Graphical network of the top 20 diseases related to Oligoastrocytoma:



Diseases related to Oligoastrocytoma

Symptoms & Phenotypes for Oligoastrocytoma

UMLS symptoms related to Oligoastrocytoma:


seizures, headache

Drugs & Therapeutics for Oligoastrocytoma

Drugs for Oligoastrocytoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 106)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Carmustine Approved, Investigational Phase 3 154-93-8 2578
2
Lomustine Approved, Investigational Phase 3 13010-47-4 3950
3
tannic acid Approved Phase 3 1401-55-4
4
Benzocaine Approved, Investigational Phase 3 94-09-7, 1994-09-7 2337
5
Histamine Approved, Investigational Phase 3 51-45-6 774
6
Cyproheptadine Approved Phase 3 129-03-3 2913
7 Interferon-alpha Phase 3
8 Dermatologic Agents Phase 3
9 Neurotransmitter Agents Phase 3
10 Histamine Antagonists Phase 3
11 Anti-Allergic Agents Phase 3
12
Histamine Phosphate Phase 3 51-74-1 65513
13 Histamine H1 Antagonists Phase 3
14 Gastrointestinal Agents Phase 3
15
Serotonin Investigational, Nutraceutical Phase 3 50-67-9 5202
16
Topotecan Approved, Investigational Phase 2 123948-87-8, 119413-54-6 60700
17
Bevacizumab Approved, Investigational Phase 1, Phase 2 216974-75-3
18
Peginterferon alfa-2a Approved, Investigational Phase 2 198153-51-4 5360545
19
Peginterferon alfa-2b Approved Phase 2 99210-65-8, 215647-85-1
20
Palbociclib Approved, Investigational Phase 2 571190-30-2 5005498 11431660 5330286
21
Leflunomide Approved, Investigational Phase 2 75706-12-6 3899
22
Mannitol Approved, Investigational Phase 1, Phase 2 69-65-8 6251 453
23
Carboplatin Approved Phase 1, Phase 2 41575-94-4 10339178 38904 498142
24
Mechlorethamine Approved, Investigational Phase 1, Phase 2 51-75-2 4033
25
Melphalan Approved Phase 1, Phase 2 148-82-3 460612 4053
26
Etoposide Approved Phase 1, Phase 2 33419-42-0 36462
27
Cetuximab Approved Phase 2 205923-56-4 56842117 2333
28
Iodine Approved, Investigational Phase 2 7553-56-2 807
29
Promethazine Approved, Investigational Phase 2 60-87-7 4927
30
Acetaminophen Approved Phase 2 103-90-2 1983
31
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 2 1177-87-3
32
Diphenhydramine Approved, Investigational Phase 2 58-73-1, 147-24-0 3100
33
Dexamethasone Approved, Investigational, Vet_approved Phase 2 50-02-2 5743
34
Temozolomide Approved, Investigational Phase 1, Phase 2 85622-93-1 5394
35
Vorinostat Approved, Investigational Phase 1, Phase 2 149647-78-9 5311
36
Panobinostat Approved, Investigational Phase 2 404950-80-7 6918837
37
Trioxsalen Approved Phase 2 3902-71-4 5585
38
Phenylalanine Approved, Investigational, Nutraceutical Phase 1, Phase 2 63-91-2 6140
39 Imatinib Mesylate Phase 1, Phase 2 220127-57-1 123596
40 Interferon alpha-2 Phase 2
41 Antiviral Agents Phase 2
42 Antineoplastic Agents, Immunological Phase 2
43 Anti-Bacterial Agents Phase 1, Phase 2
44 Immunosuppressive Agents Phase 1, Phase 2
45 Etoposide phosphate Phase 1, Phase 2
46 Antidotes Phase 1, Phase 2
47 Chelating Agents Phase 1, Phase 2
48 Antitubercular Agents Phase 1, Phase 2
49 Nitrogen Mustard Compounds Phase 1, Phase 2
50 Antioxidants Phase 1, Phase 2

Interventional clinical trials:

(show top 50) (show all 53)
# Name Status NCT ID Phase Drugs
1 A Phase III Trial on Adjuvant Standard Temozolomide Chemotherapy With or Without Interferon-alpha in Newly Diagnosed High-grade Gliomas Unknown status NCT01765088 Phase 3 Temozolomide;α-IFN
2 PRECISE - Phase III Randomized Evaluation of Convection Enhanced Delivery of IL13-PE38QQR Compared to GLIADEL® Wafer With Survival Endpoint in Glioblastoma Multiforme Patients at First Recurrence Completed NCT00076986 Phase 3 IL13-PE38QQR;prolifespan 20 with carmustine implant (GLIADEL® Wafer)
3 A Phase III Randomized Study (Phase I Closed) of Radiation Therapy and Temozolomide Versus Radiation Therapy and Nitrosourea for Anaplastic Astrocytoma And Mixed Anaplastic Oligoastrocytoma (Astrocytoma Dominant) Completed NCT00004259 Phase 3 BCNU 80mg/m2;TMZ 200mg/m2;CCNU;BCNU 150mg/m2;BCNU 200mg/m2;TMZ 150mg/m2 six 6-week cycles;TMZ 150mg/m2 six 8-week cycles
4 A Study on β-elemene as Maintain Treatment for Complete Remission Patients of Newly Diagnosed Malignant Gliomas Following Standard Treatment Recruiting NCT02629757 Phase 3 β-elemene
5 Prevention of Cancer/Treatment-Related Weight Loss in Children at High Nutritional Risk Terminated NCT01132547 Phase 3 cyproheptadine hydrochloride
6 Phase I/II Clinical Trial of the Safety, Tolerability, and Anti-tumor Efficacy of the IGF-1R Inhibitor, AXL1717 (Picropodophyllin), in the Treatment of Recurrent Malignant Astrocytomas Unknown status NCT01721577 Phase 1, Phase 2 AXL1717
7 A Phase II Open-Label, Multiple-Dose Study of Intracavitary Administered 131-I-TM-601 in Adult Patients With Recurrent High-Grade Glioma Unknown status NCT00114309 Phase 2 131-I-TM-601;131I-TM601
8 Phase II Trial of Continuous Dose Temozolomide in Patients With Newly Diagnosed Anaplastic Oligodendroglioma and Mixed Oligoastrocytoma Completed NCT00362570 Phase 2 Temozolomide
9 Phase II Trial of Continuous Dose Temozolomide in Patients With Newly Diagnosed Pure and Mixed Anaplastic Oligodendroglioma Completed NCT00400816 Phase 2 temozolomide
10 Phase I/II Trial of Imatinib Mesylate; (Gleevec; STI571) in Treatment of Recurrent Oligodendroglioma and Mixed Oligoastrocytoma Completed NCT00049127 Phase 1, Phase 2 Imatinib Mesylate
11 Open Label Phase II Study On STI571 (Glivec) Administered As A Daily Oral Treatment In Gliomas Completed NCT00039364 Phase 2 imatinib mesylate
12 A Phase II Study of Topotecan in Patients With Anaplastic Oligodendroglioma or Anaplastic Mixed Oligoastrocytoma Completed NCT00003372 Phase 2 topotecan hydrochloride
13 A Phase II Study of Prolonged Daily Temozolomide for Low-Grade Glioma Completed NCT00165360 Phase 2 Temozolomide
14 Phase I/II Adaptive Randomized Trial of Bevacizumab Versus Bevacizumab Plus Vorinostat in Adults With Recurrent Glioblastoma Completed NCT01266031 Phase 1, Phase 2 vorinostat;bevacizumab
15 A Phase II Study of Peg-Interferon Alpha-2B (Peg-Intron(TM)) and Thalidomide in Adults With Recurrent High-Grade Gliomas Completed NCT00047879 Phase 2 Thalidomide
16 Phase II Pilot, Prospective, Open Label, Multicenter CT, to Evaluate the Safety and Efficacy of Palbociclib (PD0332991), a Cyclin-dependent Kinase 4 and 6 (CDK4 and CDK6) Inhibitor, in Patients With Oligodendroglioma or Recurrent Oligoastrocytoma Anaplastic With the Activity of the Protein RB Preserved Completed NCT02530320 Phase 2 Palbociclib
17 The Efficacy and Safety of Temozolomide in Patients With Relapsed or Advanced Anaplastic Oligodendroglioma and Oligoastrocytoma: a Multicenter, Single-arm, Phase II Trial Completed NCT01847235 Phase 2 Temozolomide
18 Phase I/II Study of LBH589 and Bevacizumab in Patients With Recurrent High Grade Glioma Completed NCT00859222 Phase 1, Phase 2 LBH589;bevacizumab
19 A Phase II Open Label Study of SU101 for Patients With Anaplastic Astrocytoma in First Relapse Completed NCT00003775 Phase 2 leflunomide
20 Phase II Trial of Bevacizumab Plus Erlotinib for Patients With Recurrent Malignant Glioma Completed NCT00671970 Phase 2 Bevacizumab and Erlotinib
21 Phase I/II Study of Carboplatin, Melphalan and Etoposide Phosphate in Conjunction With Osmotic Opening of the Blood-Brain Barrier and Delayed Intravenous Sodium Thiosulfate Chemoprotection, in Previously Treated Subjects With Anaplastic Oligodendroglioma or Oligoastrocytoma Recruiting NCT00303849 Phase 1, Phase 2 Carboplatin;Etoposide;Etoposide Phosphate;Mannitol;Melphalan;Sodium Thiosulfate
22 Phase II Trial of Super Selective Intra-arterial Repeated Infusion of Cetuximab (Erbitux) With Reirradiation for Treatment of Relapsed/Refractory Glioblastoma Multiforme, Anaplastic Astrocytoma, and Anaplastic Oligoastrocytoma Recruiting NCT02800486 Phase 2 Intra-arterial Cetuximab;Intra-arterial Mannitol
23 Phase I Trial of Zotiraciclib (TG02) Plus Dose-Dense or Metronomic Temozolomide Followed by Randomized Phase II Trial of Zotiraciclib (TG02) Plus Temozolomide Versus Temozolomide Alone in Adults With Recurrent Anaplastic Astrocytoma and Glioblastoma Recruiting NCT02942264 Phase 1, Phase 2 Zotiraciclib (TG02);TMZ
24 Phase II Study of Intrathecal I-3F8 in Patients With GD2-Expressing Central Nervous System and Leptomeningeal Neoplasms Active, not recruiting NCT00445965 Phase 2
25 A Phase II Study of Temozolomide and O6-Benzylguanine (O6-BG) in Patients With Temozolomide-Resistant Anaplastic Glioma Terminated NCT00389090 Phase 2 Temozolomide and O6-Benzylguanine
26 A Phase II Study of Photodynamic Therapy (PDT) With Photofrin® (IND 104,613) For Recurrent High Grade Gliomas in Adults Terminated NCT01966809 Phase 2 Photofrin photodynamic therapy.
27 Phase II Trial of LBH589 (Panobinostat) in Adult Patients With Recurrent Malignant Gliomas Terminated NCT00848523 Phase 2 Panobinostat
28 Phase I / II Adaptive Randomized Trial of Vorinostat, Erlotinib and Temozolomide in Adults With Recurrent Glioblastoma Multiforme Terminated NCT01110876 Phase 1, Phase 2 Vorinostat;Erlotinib;Temozolomide
29 Phase 2 Study of IDH305 in Subjects With IDH1 Mutant Grade II or III Glioma That Has Progressed After Observation or Radiation Therapy Withdrawn NCT02977689 Phase 2 IDH305
30 Phase I/II Trial of Cabazitaxel in Adult Patients With Recurrent Malignant Glioma Withdrawn NCT01740570 Phase 1, Phase 2 Cabazitaxel
31 Photodynamic Therapy For Childhood Brain Tumors, A Phase I Study Unknown status NCT00002647 Phase 1 verteporfin
32 A Phase I Trial of Nanoliposomal CPT-11 (NL CPT-11) in Patients With Recurrent High-Grade Gliomas Completed NCT00734682 Phase 1 Nanoliposomal CPT-11
33 Evaluation of FDOPA-PET/MRI in Pediatric Patients With CNS Tumors, A Feasibility Study Completed NCT01999270 Phase 1 Irinotecan;Bevacizumab
34 Phase I Study of Convection Enhanced Delivery (CED) of IL13-PE38QQR Infusion After Resection Followed by Radiation Therapy With or Without Temozolomide in Patients With Newly Diagnosed Supratentorial Malignant Glioma Completed NCT00089427 Phase 1 IL13-PE38QQR;Temozolomide with radiation therapy
35 Phase I Trial of Super-Selective Intraarterial Intracranial Infusion of Avastin (Bevacizumab) For Treatment of Relapsed/Refractory Glioblastoma Multiforme and Anaplastic Astrocytoma Completed NCT00968240 Phase 1 Super-Selective Intraarterial Intracranial Infusion of BEVACIZUMAB
36 Phase I Dose Finding Study of Sorafenib in Combination With Radiation Therapy and Temozolomide as a First Line Treatment of Patients With High Grade Glioma Completed NCT00884416 Phase 1 Sorafenib dose escalation
37 A Phase 1 Ascending Dose Trial of the Safety and Tolerability of Toca 511 in Patients With Recurrent High Grade Glioma Completed NCT01156584 Phase 1 Toca FC
38 A Phase 1 Study of Imetelstat, a Telomerase Inhibitor, in Children With Refractory or Recurrent Solid Tumors and Lymphomas Completed NCT01273090 Phase 1 imetelstat sodium
39 A Phase 1 Ascending Dose Trial of the Safety and Tolerability of Toca 511, a Retroviral Replicating Vector, Administered Intravenously Prior to, and Intracranially at the Time of, Subsequent Resection for Recurrent HGG & Followed by Treatment With Extended-Release 5-FC Completed NCT01985256 Phase 1 Toca FC
40 A Phase 1 Ascending Dose Trial of Safety and Tolerability of Toca 511, a Retroviral Replicating Vector, Administered to Subjects at the Time of Resection for Recurrent High Grade Glioma & Followed by Treatment With Toca FC, Extended-Release 5-FC Completed NCT01470794 Phase 1 Toca FC
41 A Phase I Study of SU011248 Plus Irinotecan in the Treatment of Patients With Malignant Glioma Completed NCT00611728 Phase 1 SU011248 & Irinotecan
42 A Phase I Trial of the Addition of the Farnesyl Transferase Inhibitor, SCH 66336, to Temodar for Patients With Grade 3 and 4 Malignant Gliomas Completed NCT00612651 Phase 1 Temodar and SCH 66336
43 A Phase I Dose Escalation and Central Nervous System (CNS) Pharmacokinetic Study of the ErbB Family Inhibitor Afatinib in Patients With Recurrent or Progressive Brain Cancer Recruiting NCT02423525 Phase 1 Afatinib
44 Phase Ib Study of Oncolytic Polio/Rhinovirus Recombinant Against Recurrent Malignant Glioma in Children Recruiting NCT03043391 Phase 1
45 A Continuation Protocol for Patients Previously Enrolled in a Study of Toca 511 Terminated NCT04327011 Phase 1 Toca FC • Flucytosine • 5-FC • 5-Fluorocytosine
46 Phase I Trial of Irinotecan Plus Lenalidomide in Adult Patients With Recurrent Glioblastoma Multiforme Terminated NCT00671801 Phase 1 Irinotecan;Lenalidomide
47 Imaging After Stereotactic Radiosurgery for Brain Metastases or Primary Tumor Can Hybrid PET-MRI Differentiate Between Radiation Effects and Disease ? Unknown status NCT03068520
48 A Bi-Institutional Pilot Study to Evaluate the Effects of Vaccinations With HLA-A2-Restricted Glioma Antigen-Peptides in Combination With Poly-ICLC for Adults With WHO Grade II Low-Grade Gliomas Completed NCT00795457 Early Phase 1
49 Diagnostic And Prognostic Markers In High-Grade Glioma Completed NCT01004887
50 The Neural Basis of Language: A New Lighting. Study of Semantic Processing in MRI Mutimodale and Direct Electrical Stimulation Completed NCT02903784

Search NIH Clinical Center for Oligoastrocytoma

Genetic Tests for Oligoastrocytoma

Genetic tests related to Oligoastrocytoma:

# Genetic test Affiliating Genes
1 Oligoastrocytoma 29

Anatomical Context for Oligoastrocytoma

MalaCards organs/tissues related to Oligoastrocytoma:

40
Brain, Testes, Spinal Cord, Eye, Bone, Bone Marrow, Temporal Lobe

Publications for Oligoastrocytoma

Articles related to Oligoastrocytoma:

(show top 50) (show all 512)
# Title Authors PMID Year
1
Low expression of FOSL1 is associated with favorable prognosis and sensitivity to radiation/pharmaceutical therapy in lower grade glioma. 61
32245342 2020
2
Nuclear H3 K27me3 is retained in both components of dual genotype oligoastrocytoma. 61
32383207 2020
3
Pediatric Kidney Transplantation in Perú: A Single-Center Initial Experience. 61
32115239 2020
4
Phase I clinical trial of temsirolimus and perifosine for recurrent glioblastoma. 61
32293798 2020
5
Surgical treatment of low-grade brain tumors associated with epilepsy. 61
32448606 2020
6
Oligo-astrocytoma in LZTR1-related Noonan syndrome. 61
30664951 2020
7
Early versus delayed postoperative radiotherapy for treatment of low-grade gliomas. 61
31958162 2020
8
Acute and chronic hemorrhage from radiation-induced cavernous malformation associated with late-delayed radiation necrosis in long surviving glioma patients: A case report. 61
31897165 2020
9
The crystal structure of Capicua HMG-box domain complexed with the ETV5-DNA and its implications for Capicua-mediated cancers. 61
31323153 2019
10
Correction to: Phase I-II trial of imatinib mesylate (Gleevec; STI571) in treatment of recurrent oligodendroglioma and mixed oligoastrocytoma. North central cancer treatment group study N0272 (ALLIANCE/NCCTG). 61
31165953 2019
11
Incidence trends of adult malignant brain tumors in Finland, 1990-2016. 61
30985227 2019
12
Phase I-II trial of imatinib mesylate (Gleevec; STI571) in treatment of recurrent oligodendroglioma and mixed oligoastrocytoma. North central cancer treatment group study N0272 (ALLIANCE/NCCTG). 61
31119479 2019
13
The Applicability of Haarlem Integrated Diagnostic System in Diffuse Glial Tumors and Molecular Methods Affecting Prognosis 61
30592195 2019
14
The pan-cancer mutational landscape of the PPAR pathway reveals universal patterns of dysregulated metabolism and interactions with tumor immunity and hypoxia. 61
31215667 2019
15
Brain cancer survival in Canada 1996-2008: effects of sociodemographic characteristics. 61
31285671 2019
16
von Willebrand Factor Gene Expression in Primary Lower Grade Glioma: Mutually Co-Occurring Mutations in von Willebrand Factor, ATRX, and TP53. 61
31062529 2019
17
Sequencing of Chemotherapy and Radiotherapy for Newly Diagnosed Anaplastic Oligodendroglioma and Oligoastrocytoma. 61
30601146 2019
18
Comparison of Radiation Therapy Alone and Chemotherapy Alone for Low-Grade Gliomas without Surgical Resection. 61
30261385 2019
19
Allergy may confer better survival on patients with gliomas. 61
30611004 2019
20
A Pilot Study of Vaccine Therapy with Multiple Glioma Oncoantigen/Glioma Angiogenesis-Associated Antigen Peptides for Patients with Recurrent/Progressive High-Grade Glioma. 61
30791546 2019
21
Molecular features and clinical outcomes in surgically treated low-grade diffuse gliomas in patients over the age of 60. 61
30498891 2019
22
Recurrent Glioma With Lineage Conversion From Oligodendroglioma to Astrocytoma in Two Cases. 61
31508376 2019
23
Engrailed 1 overexpression as a potential prognostic marker in Lower Grade Glioma. 61
31576231 2019
24
Neurosurgical therapy for Status Epilepticus in Oligoastrocytoma Patient: A case report. 61
30682510 2019
25
Successful treatment of a BRAF V600E-mutant extracranial metastatic anaplastic oligoastrocytoma with vemurafenib and everolimus. 61
30462564 2019
26
Impact of adjuvant treatments on survival in Korean patients with WHO grade II gliomas: KNOG 15-02 and KROG 16-04 intergroup study. 61
30097825 2018
27
Association of MGMT Promoter Methylation Status With Survival Outcomes in Patients With High-Risk Glioma Treated With Radiotherapy and Temozolomide: An Analysis From the NRG Oncology/RTOG 0424 Trial. 61
29955793 2018
28
Age and surgical outcome of low-grade glioma in Sweden. 61
29900547 2018
29
Increased HSPG2 expression independently predicts poor survival in patients with oligoastrocytoma and oligodendroglioma. 61
30402850 2018
30
Diffuse low-grade glioma mimicking ischaemic infarct: a case report. 61
29384395 2018
31
Possibility of venoarterial extracorporeal membranous oxygenator being a bridging therapy for hemodynamic deterioration of pulmonary tumor thrombotic microangiopathy prior to initiating chemotherapy: A case report. 61
30212945 2018
32
Outcomes for Anaplastic Glioma Treated With Radiation Therapy With or Without Concurrent Temozolomide. 61
28301347 2018
33
Extracranial metastasis of anaplastic oligoastrocytoma. 61
30197798 2018
34
Correction to: SEOM clinical guidelines for anaplastic gliomas (2017). 61
29858734 2018
35
Threshold of the extent of resection for WHO Grade III gliomas: retrospective volumetric analysis of 122 cases using intraoperative MRI. 61
28885120 2018
36
Multi-institutional study of treatment patterns in Korean patients with WHO grade II gliomas: KNOG 15-02 and KROG 16-04 intergroup study. 61
29572674 2018
37
Symptomatic Remote Cyst after BCNU Wafer Implantation for Malignant Glioma. 61
29780071 2018
38
A simple algorithmic approach using histology and immunohistochemistry for the current classification of adult diffuse glioma in a resource-limited set-up. 61
28801347 2018
39
The 2016 revision of the WHO Classification of Central Nervous System Tumours: retrospective application to a cohort of diffuse gliomas. 61
29218432 2018
40
WHO 2016 Classification of gliomas. 61
28815663 2018
41
SEOM clinical guidelines for anaplastic gliomas (2017). 61
29058264 2018
42
SEOM clinical guideline of diagnosis and management of low-grade glioma (2017). 61
29124520 2018
43
Intraoperative Squash and Touch Preparation Cytology of Brain Lesions Stained with H+E and Diff-Quik™: A 20-Year Retrospective Analysis and Comparative Literature Review. 61
28977789 2018
44
Feline glioma: a retrospective study and review of the literature. 61
28156189 2017
45
2016 Updates to the WHO Brain Tumor Classification System: What the Radiologist Needs to Know. 61
29028423 2017
46
Rates of Seizure Freedom After Surgical Resection of Diffuse Low-Grade Gliomas. 61
28673890 2017
47
Mapping an Extended Neurochemical Profile at 3 and 7 T Using Accelerated High-Resolution Proton Magnetic Resonance Spectroscopic Imaging. 61
28459799 2017
48
Multicenter phase II study of temozolomide and myeloablative chemotherapy with autologous stem cell transplant for newly diagnosed anaplastic oligodendroglioma. 61
28472509 2017
49
Spinal metastases of two different grade oligodendrogliomas: a case report and review of literature. 61
29057359 2017
50
Prognostic relevance of NG2/CSPG4, CD44 and Ki-67 in patients with glioblastoma. 61
28945172 2017

Variations for Oligoastrocytoma

Expression for Oligoastrocytoma

Search GEO for disease gene expression data for Oligoastrocytoma.

Pathways for Oligoastrocytoma

GO Terms for Oligoastrocytoma

Biological processes related to Oligoastrocytoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular matrix organization GO:0030198 8.62 HSPG2 GFAP

Sources for Oligoastrocytoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....